Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced bre...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kaufman, Bella, Stein, Steven, Casey, Michelle A, Newstat, Beth O
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2008
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727787/
https://ncbi.nlm.nih.gov/pubmed/19707428
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki